Study: Immune Anticancer Agents Can Increase the Risk of Diabetes
Study also indicates that patients at highest risk of developing diabetes can be detected by pre-screaning and treatment plans can be formulated
Immune anticancer agents are the most attention-grabbing anticancer therapeutic agents in recent years. However, a study in South Korea showed that in the patients studied, their use increased the risk of developing diabetes compared to conventional chemotherapy. Shutterstock
Immune anticancer agents are drugs that prevent cancer cells from evading the body’s immune system or enable immune cells to better recognize and attack the cancer cells. They are the most attention-grabbing anticancer therapeutic agents in recent years.
Immunotherapy, also known as biologic therapy, refers to using the body’s immune system to fight cancer. Cancer cells can live unchecked in the body because the immune system does not recognize them as an invader. Immunotherapy helps the immune system “see” cancer and attack it.
Immunotherapy has Little Impact on Normal Cells
The first immunotherapy drug to treat cancer was approved by the U.S. Food and Drug Administration (FDA) in 2011. Since then, immunotherapy has developed rapidly and become one of the important means of cancer treatment.[1]
Lisa Bian, B.Med.Sc., is a healthcare professional holding a Bachelor's Degree in Medical Science. With a rich background, she has accrued over three years of hands-on experience as a Traditional Chinese Medicine physician. In addition to her clinical expertise, she serves as an accomplished writer based in Korea, providing valuable contributions to The Epoch Times. Her insightful pieces cover a range of topics, including integrative medicine, Korean society, culture, and international relations.
